文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

新辅助纳武利尤单抗治疗后发生迟发性细胞因子释放综合征:病例报告及文献复习。

Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.

机构信息

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.

Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA.

出版信息

Immunotherapy. 2021 Sep;13(13):1071-1078. doi: 10.2217/imt-2020-0329. Epub 2021 Jul 21.


DOI:10.2217/imt-2020-0329
PMID:34287029
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8656293/
Abstract

Cytokine release syndrome (CRS) is an infrequently described immune-related adverse event of checkpoint inhibitors (CPI). CPI-induced CRS typically presents with fevers, hemodynamic instability and organ dysfunction within 2 weeks of the last treatment cycle. We report an unusual case of delayed and severe CRS occurring postoperatively in a patient with hepatic-limited metastatic colorectal cancer who received neoadjuvant immunotherapy. After a negative workup for alternative causes, he received prolonged corticosteroid treatment with symptom resolution. CPI-induced CRS can mimic sepsis and clinicians should maintain a high-index of suspicion to diagnose this immune-related adverse event early and initiate appropriate treatment. As use of perioperative immunotherapy increases, the potential role of surgery to trigger CRS in this case warrants further investigation.

摘要

细胞因子释放综合征(CRS)是一种罕见的免疫相关不良事件,发生于检查点抑制剂(CPI)治疗后。CPI 引起的 CRS 通常在最后一个治疗周期后 2 周内出现发热、血流动力学不稳定和器官功能障碍。我们报告了一例罕见的肝转移结直肠癌患者新辅助免疫治疗后延迟和严重 CRS 的病例。在排除其他原因后,他接受了长期皮质类固醇治疗,症状缓解。CPI 引起的 CRS 可模拟脓毒症,临床医生应保持高度警惕,早期诊断这种免疫相关不良事件,并进行适当的治疗。随着围手术期免疫治疗的应用增加,在这种情况下手术触发 CRS 的潜在作用值得进一步研究。

相似文献

[1]
Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.

Immunotherapy. 2021-9

[2]
Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature.

Front Immunol. 2022

[3]
Tocilizumab and CytoSorb for delayed severe cytokine release syndrome after ipilimumab plus nivolumab immunotherapy.

Immunotherapy. 2024

[4]
Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer.

Intern Med. 2024-5-1

[5]
Nivolumab-Induced Cytokine Release Syndrome: A Case Report and Literature Review.

Am J Case Rep. 2024-4-16

[6]
Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release Syndrome.

Cancer Rep (Hoboken). 2024-7

[7]
Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden.

Oncoimmunology. 2024

[8]
A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer.

Thorac Cancer. 2022-10

[9]
Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.

Intern Med. 2021-11-1

[10]
Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.

J Immunother Cancer. 2023-3

引用本文的文献

[1]
Innovative CDR grafting and computational methods for PD-1 specific nanobody design.

Front Bioinform. 2025-1-17

[2]
Tislelizumab-induced cytokine release syndrome: the first case report and review of the literature.

Immunotherapy. 2024

[3]
Cytokine release syndrome following COVID-19 infection during treatment with nivolumab for cancer of esophagogastric junction carcinoma: a case report and review.

Int J Emerg Med. 2024-9-2

[4]
Tocilizumab and CytoSorb for delayed severe cytokine release syndrome after ipilimumab plus nivolumab immunotherapy.

Immunotherapy. 2024

[5]
Herb pair of Huangqi-Danggui exerts anti-tumor immunity to breast cancer by upregulating PIK3R1.

Animal Model Exp Med. 2024-6

[6]
Nivolumab-Induced Cytokine Release Syndrome: A Case Report and Literature Review.

Am J Case Rep. 2024-4-16

[7]
Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients - A case report and review of the literature.

Heliyon. 2024-1-10

[8]
Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1-positive patient with advanced non-small cell lung cancer.

Front Pharmacol. 2023-2-2

[9]
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome.

Cancers (Basel). 2023-1-3

[10]
Cytokine Release Syndrome and Sepsis: Analogous Clinical Syndromes with Distinct Causes and Challenges in Management.

Infect Dis Clin North Am. 2022-12

本文引用的文献

[1]
Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database.

Front Pharmacol. 2020-5-4

[2]
Checkpoint inhibitor immunotherapy in kidney cancer.

Nat Rev Urol. 2020-2-4

[3]
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018.

Transl Lung Cancer Res. 2019-12

[4]
A review of cancer immunotherapy toxicity.

CA Cancer J Clin. 2020-1-16

[5]
Pooled analysis of T2 Candida for rapid diagnosis of candidiasis.

BMC Infect Dis. 2019-9-11

[6]
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.

Semin Cancer Biol. 2019-8-17

[7]
Immune checkpoint inhibitors: The linchpins of modern immunotherapy.

Immunol Rev. 2019-7

[8]
First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer.

Case Rep Oncol. 2019-2-8

[9]
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.

Clin Cancer Res. 2019-4-30

[10]
Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report.

J Immunother Cancer. 2019-4-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索